Molecular modification of immunotherapeutic agents can increase the body's resistance to cancer.

Published Date: 08 Mar 2023

On the road, put your foot on the accelerator or brake pedal to control the speed of the car. It also happens in our body, causing the immune system. Like human drivers, vaccines also have "feet" or "push" molecular legs.

Read Full News

Latest News

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion

FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion

Increases in Physician Attrition Rates Could Worsen Shortages

Increases in Physician Attrition Rates Could Worsen Shortages

Improving CRC Screening Rates With High-Quality, Noninvasive Tests, with Keith Winfrey, MD, MPH Keith Winfrey, MD, MPH

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

ACP Urges Concern for Health Policy Issues, with Shari Erickson, MPH Shari Erickson, MPH

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

Reviving exhausted immune cells boosts tumor elimination

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Todays Updates

Phase 3b RESHAPE Study Evaluates Risk–Benefit of Switching From Ocrelizumab to BTK Inhibitor Remibrutinib Isabella Ciccone, MPH

A phase 3b study presented at ACTRIMS 2026 is evaluating whether switching to remibrutinib offers efficacy and safety comparable to continued ocrelizumab treatment in relapsing multiple sclerosis.

Latest News

FDA Approves New Narcan Packaging, Aiming to Boost Carry Rates

FDA Approves Tradipitant (NEREUS) for the Prevention of Vomiting Induced by Motion

Increases in Physician Attrition Rates Could Worsen Shortages

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

A new study has discovered a molecular signal that tumors exploit to exhaust the T cells meant to destroy them—and how silencing that signal could revive the body's immunity.

News All Time

Gut bacterium may sabotage liver cancer immunotherapy, study suggests

A research team led by the Department of Clinical Oncology, Center of Cancer Medicine, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has identified a critical factor contributing ...

Cellular protein FGD3 boosts breast cancer chemotherapy and immunotherapy, study finds

A naturally-occurring protein that tends to be expressed at higher levels in breast cancer cells boosts the effectiveness of some anticancer agents, including doxorubicin, one of the most widely used chemotherapies, and a ...

Global reviews call for urgent action on endometriosis in most world regions

Two reviews published in The Lancet Obstetrics, Gynecology & Women's Health reveal stark global inequities in how endometriosis is recognized, treated, and prioritized in national health systems.

Mental and physical coaching before surgery prepares immune system and reduces complications, trial finds

The weeks leading up to a major surgery can be a time of uncertainty and worry for patients, many of whom anticipate the need for rehabilitation to get back on their feet. But if patients improve their physical and mental ...

Flu vaccine performance varies by age, study reveals

New research comparing four different flu vaccines found that the ability of the vaccines to activate cells of the immune system that help to protect against infection varied greatly depending on the vaccine type and age ...

Study reveals why some myeloma patients stay cancer-free for years after CAR T therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see ...

Researchers aim to disrupt breast cancer line of communication and prevent spread

Cancer Center at Illinois (CCIL) Program Leader Erik Nelson's lab made an important discovery about the relationship between cholesterol and breast cancer progression with crucial implications for breast cancer therapeutics.

Study tracking how tumor microenvironment develops signals opportunity for early detection, risk prediction

Colorectal cancer precursor lesions are benign growths that can develop into colorectal cancer (CRC) over time, through either a conventional or serrated pathway. Understanding how the immune system reacts to these precursor ...

Rapid growth of radiopharmaceutical therapy highlights need for expertise

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining the education, training, and experience needed to ensure the safe and effective delivery of radiopharmaceutical therapy ...

Blood test offers hope for more effective ovarian cancer treatment

New clinical research has identified a blood test that can reveal which women are more likely to respond to a particular treatment for ovarian cancer, known as PARP inhibitor therapy.

T cell therapies show long-term HPV gains

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center ...

FDA grants fast track designation to drug combo for colorectal cancer

The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma ...

Q&A: Connection between a distinct immune cell and colitis discovered

CU Anschutz researchers uncovered a link between a type of mucosal immune cell and gut inflammation, finding that the cells exacerbate inflammation and lead to chronic disease in certain conditions.

Newly identified lymphoma subtype gives hope in fight against aggressive form of blood cancer

Researchers at the University of Southampton have identified a new subtype of lymphoma that could pave the way to improved and more targeted treatments for some blood cancer patients. The cancer scientists and biologists ...

Sleep issues linked to higher risk of severe asthma in children

About 30 to 40% of children with asthma experience sleep difficulties due to symptoms like coughing and wheezing. Poor sleep increases the risk of severe asthma exacerbations (attacks) that often necessitate a hospitalization ...

What is myasthenia gravis, the rare disease tennis great Monica Seles lives with?

Former tennis star Monica Seles recently revealed she is living with the rare disease myasthenia gravis, which affects 12 in 100,000 people globally.

Recommended News For You

A new theranostic drug targets different cancer types.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

According to JAMA, statin use may increase cancer-related survival in breast cancer patients.

Hit and Miss for CDK4/6 Inhibitor in Recurrent Brain Cancer

Breast density changes over time are associated with an increased risk of cancer.

In early dementia, SSRIs enhance cognition and major depression.

How wildfires pose challenges to cancer care

Recommended Articles For You

CAR-T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia: A Comprehensive Review 

Revolutionizing Cancer Treatment: How Adoptive Cell Therapy is Overcoming Tumor Immune Evasion 

Precision Medicine and Genomics: Revolutionizing Healthcare Through Personalized Treatment 

Bridging Heart and Cancer Care: The Essential Framework of a Modern Cardio-Oncology Program 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

2.

Unlocking the potential of targeted therapies for multiple myeloma

3.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

4.

Q&A: Odds of surviving cancer drop drastically when credit score dips

5.

Children with rare gliomas have new hope thanks to clinical trial results.

1.

Understanding the HAS-BLED Score: What It Is and Why It Matters 

2.

Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study

3.

Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025

4.

A Comprehensive Guide to Carcinoma in Situ: Types, Risks, and Preventive Measures

5.

Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Navigating the Complexities of Ph Negative ALL - Part XIII

2.

Navigating the Complexities of Ph Negative ALL - Part II

3.

Should We Use DARA Up Front As First-Line Therapy in MM?

4.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot